Coronation Fund Managers Ltd. Has $17.14 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Coronation Fund Managers Ltd. grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 34.4% during the 1st quarter, Holdings Channel reports. The firm owned 100,522 shares of the medical research company’s stock after buying an additional 25,739 shares during the period. IQVIA comprises about 0.8% of Coronation Fund Managers Ltd.’s investment portfolio, making the stock its 24th biggest position. Coronation Fund Managers Ltd.’s holdings in IQVIA were worth $17,143,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Militia Capital Management LLC bought a new position in shares of IQVIA in the first quarter valued at $2,899,000. CI Investments Inc. raised its position in IQVIA by 57.0% during the first quarter. CI Investments Inc. now owns 176,021 shares of the medical research company’s stock worth $30,019,000 after acquiring an additional 63,900 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new stake in IQVIA in the first quarter valued at $36,012,000. ABN Amro Investment Solutions grew its position in shares of IQVIA by 51.1% in the 1st quarter. ABN Amro Investment Solutions now owns 9,557 shares of the medical research company’s stock valued at $1,630,000 after acquiring an additional 3,234 shares during the period. Finally, Oslo Pensjonsforsikring AS acquired a new position in shares of IQVIA during the 1st quarter worth about $347,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 1.3%

IQV opened at $198.96 on Thursday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a fifty day moving average of $186.73 and a 200-day moving average of $187.36. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The company has a market capitalization of $33.21 billion, a P/E ratio of 24.65, a P/E/G ratio of 1.81 and a beta of 1.20.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the firm earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its board has initiated a stock repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on IQV shares. Evercore reiterated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Robert W. Baird raised their price objective on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research note on Thursday, July 9th. Mizuho boosted their target price on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Thirteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $225.71.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.